Antimicrobial Resistant Organism Decolonization After Microbiome Perturbation
Stopped: Study intervention not available. Manufacturer no longer producing MET-2.
Canada0Started 2026-07
Plain-language summary
ARO-DECAMP is a multi-centre, placebo-controlled, pilot and feasibility randomized controlled trial for the microbial consortium Microbial Ecosystem Therapeutic-2. Non-intensive care unit patients ≥ 18 years old diagnosed with a bloodstream infection and receiving treatment for an antibiotic resistant organism will be included. Participants will be randomized to receive either MET-2 or placebo for 10 days. Recruitment rate and study intervention adherence will be evaluated for feasibility. Participants will be followed for 180 days, and biological samples will be collected periodically for clinical, ecological, and biomarker outcomes.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Adult (≥18 years old) inpatient not admitted to the ICU or equivalent (step-up and step-down units are eligible)
✓. Positive blood culture with an ARO:
✓. Currently receiving treatment for the bloodstream infection
Exclusion criteria
✕. Inability to swallow oral MET-2 or placebo capsule
✕. Recipient of small bowel transplant
✕. Inflammatory bowel disease, short bowel syndrome, diverting/non-diverting ileo/colostomy
✕. Use of \>3 days over-the-counter or prescription probiotics (not including food additives) within 10 days of enrolment
✕. Receipt of fecal microbiota transplant (FMT) within 3 months of enrolment
✕. Absolute neutrophil count \<0.5x109/L
✕. Death expected within 72 hours of enrolment
What they're measuring
1
Recruitment rate overall and by study site
Timeframe: 1.5 years
2
Adherence to MET-2/placebo for the treatment duration